• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

US FDA approves generic versions of Novartis blockbuster MS treatment

expresspharmaDecember 09, 2019

Tag: FDA , Novartis , MS treatment

The US Food and Drug Administration approved three generic versions of Swiss drugmaker Novartis AG’s top-selling multiple sclerosis (MS) medicine Gilenya.

The approval allows HEC Pharm Co, Biocon and Sun Pharmaceutical Industries to produce the drug for the treatment of relapsing forms of MS in adult patients.

Novartis was defending patents on Gilenya in the United States to block generic rivals.

Earlier in June, US federal court order had prevented rival generic makers from selling versions of Gilenya in the United States.

Nearly a decade after its US approval, Gilenya remains Novartis’s number two revenue generator at $829 million in the third quarter.

Previous:ImCheck raises Series B funds to develop gamma delta therapies

Next:FDA approves first generics of Gilenya

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

US FDA approves generic versions of Novartis blockbuster MS treatment | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Nabumetone (FDA)

Nabumetone (FDA)
Hemisuccinate /Sodium (FDA/DMF)

Hemisuccinate /Sodium (FDA/DMF)
Vecuronium (FDA)

Vecuronium (FDA)
Cyclosporin A (FDA)

Cyclosporin A (FDA)
Fluorfenicol( FDA)

Fluorfenicol( FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Diosmin(CEP FDA GMP)

Diosmin(CEP FDA GMP)
Sirolimus (FDA)

Sirolimus (FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service